Sign in
CompletedNo phase

Financial Toxicity and Quality of Life in Patients With TGCT

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the site
Trial code
Status
Completed
People taking part
24 people enrolled
Started
1 Mar 2023
Ended
4 Feb 2025
Type of study
Observational
Treatments tested
  • Comprehensive Score for financial toxicity (COST)
  • Functional Assessment of Cancer Therapy: General (FACT-G)
  • EORTC QLQ C-30
  • EORTC QLQ-TC26.
Record updated
14 July 2025

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Age > 18 years of age
  • Patients with histologically or clinically confirmed germ cell tumor
  • Completed treatment for germ cell tumor with multicycle (> 2 cycles) / multiagent chemotherapy
  • Within years 1-5 of surveillance since Day 1 of last cycle of chemotherapy
  • Signed informed consent

Who cannot take part

  • Long-term survivors; Patients undergoing active chemotherapy; Patients who did not complete 1st line chemotherapy

Where in United States

  • Mays Cancer CenterSan Antonio, United States

About the trial

What the trial wants to find out

This is a cross-sectional, observational study employing validated questionnaires to investigate financial toxicity in subjects with testicular germ cell tumors (TGCT). As background, TGCTs are the most common malignancies among men from age 15-35. Treatment is highly curative, but often consists of intensive multi-cycle chemotherapy with significant potential for physical toxicity. The treatment course itself is disruptive and long term physical and mental health consequences can increase risk for financial toxicity. Thus, we aim to study financial toxicity in both patients with TGCT actively receiving treatment and in TGCT survivors. There will be two separate cohorts: Cohort 1 will consist of subjects with recently diagnosed TGCT who will undergo multi-agent, multi-cycle chemotherapy and Cohort 2 will consist of subjects who have completed chemotherapy and are long-term survivors.

The group in the trial

  • Long-term survivors of TGCT

    Treatment: Comprehensive Score for financial toxicity (COST), Functional Assessment of Cancer Therapy: General (FACT-G), EORTC QLQ C-30, and EORTC QLQ-TC26.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Financial Toxicity and Quality of Life in Patients With Testicular Germ Cell Tumors
Record updated
14 July 2025